In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Compass Biomedical

www.compassbiomed.com

Latest From Compass Biomedical

Deals Shaping the Medical Industry (12/07)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Windhover's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

Business & Technology Briefs (11/2007)

Brief summaries of recent product and company developments in the device industry, including: poor acceptance dooms Exubera inhaled insulin; QLT bets big on ForSight plug; hot markets, lukewarm IPOs; Arteriocyte Medical launches; Synthes buys N Spine.
Medical Device

Succeeding in Heart Failure, Incrementally

Because of the heterogeneity of heart failure patients and causes, new drugs to treat heart failure haven't been a huge area of research or business development. Few heart failure drugs are likely to be blockbusters, and there are very few deals around truly novel targets. Biotech start-ups build on known approaches and innovate incrementally, in this market.
BioPharmaceutical Strategy

European Markets for Prosthetic Vascular Grafts

Many large and growing diseases, such as diabetes, cause vessel damage calling for replacement vascular grafts. The European market for prosthetic vascular grafts is today a $343 million industry and growing, according to "The European Prosthetic Vascular Grafts Market," a report just issued y Medtech Insight.
Medical Device Europe
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Alias(es)
  • Arteriocyte Inc.
  • Arteriocyte Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Compass Biomedical
  • Senior Management
  • Donald Brown, CEO
    Kolby Day, VP, General Mgr., R&D
  • Contact Info
  • Compass Biomedical
    Phone: (855) 475-7587
    7100 Euclid Ave.
    Cleveland, OH 44103
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register